Does Serotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer's Dementia?
- 1 October 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 27 (5), 484-487
- https://doi.org/10.1097/jcp.0b013e31814b98c1
Abstract
Recent studies suggest that cholinergic dysfunction does not provide a complete account of age-related cognitive deficits, and other neuronal systems like monoaminergic hypofunction are involved. In several studies, selective serotonin reuptake inhibitors demonstrated promotion in neurogenesis in the hippocampus and enhanced memory and cognition. The aim of this study is to survey the effect of serotonin augmentation on cognition and activities of daily living in patients with Alzheimer's disease. The trial was designed as a 12-week randomized, placebo-controlled, double-blind study. One hundred twenty-two patients aged 55 to 85 years with mild-to-moderate Alzheimer's dementia were randomly allocated in 1 of the 3 treatment groups: fluoxetine plus rivastigmine, rivastigmine alone, or placebo group. Efficacy measures comprised assessments of cognition, activities of daily living, and global functioning. Hamilton Depression Scale also was used to assess changes in mood throughout the study. Fluoxetine plus rivastigmine and rivastigmine groups demonstrated improvement on measures of cognitive and memory without any significant difference; however, the former group did better in their activities of daily living and global functioning. Patients taking placebo had significant deterioration in all the efficacy measures. Patients taking rivastigmine or rivastigmine plus fluoxetine had improvements in Hamilton Depression Scale without significant differences. Concomitant use of selective serotonin-enhancing agents and acetyl cholinesterase inhibitors can provide greater benefit in activities of daily living and global functioning in patients with cognitive impairment. Because our study is preliminary, larger double-blind studies are needed to confirm the results.Keywords
This publication has 25 references indexed in Scilit:
- Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptomsBiological Psychiatry, 2005
- Pharmacological Characterization of RS-1259, an Orally Active Dual Inhibitor of Acetylcholinesterase and Serotonin Transporter, in Rodents: Possible Treatment of Alzheimer’s DiseaseJournal of Pharmacological Sciences, 2003
- Postmortem serotoninergic correlates of cognitive decline in Alzheimer??s diseaseNeuroReport, 2002
- Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional ImagingNeuropsychopharmacology, 1998
- Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behaviorBrain Research, 1994
- Monoamine neurons in aging and Alzheimer's diseaseJournal of Neural Transmission, 1993
- Temporal Lobe Atrophy on Magnetic Resonance Imaging in the Diagnosis of Early Alzheimer's DiseaseArchives of Neurology, 1993
- The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memorySynapse, 1991
- Age-related changes in multiple neurotransmitter systems in the monkey brainNeurobiology of Aging, 1989
- NON-CHOLINERGIC NEUROTRANSMITTER ABNORMALITIES IN ALZHEIMER'S DISEASEBritish Medical Bulletin, 1986